RFK Jr. Clears 6 Peptides for Compounding, Overruling FDA Staff

Health and Human Services Secretary Robert F. Kennedy Jr. has issued a new policy that lets specialty compounding pharmacies sell six peptide drugs, reversing a 2023 Food and Drug Administration decision that removed those same peptides from the approved compounding list, according to Ars Technica.

What Rule Did HHS Just Publish?

The policy, titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," appeared in the Federal Register on Wednesday with a final publication date of October 30, Ars Technica reports. The rule does not restore the peptides' formal regulatory status as approved compounding ingredients. Instead, HHS says it will simply decline to take enforcement action against pharmacies that make and sell them — a practical green light without the rulemaking process normally required to undo an FDA decision.

Which Six Peptides Are Now Covered?

The policy applies to BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, according to the HHS explanation cited by Ars Technica. All six are popular within Kennedy's Make America Health Again movement, and the outlet reports that many prominent MAHA figures and Kennedy allies sell the compounds. Kennedy told Ars Technica he uses some of the peptides himself and called himself "a big fan."

Why Did FDA Scientists Object?

FDA scientists removed the six peptides from the approved compounding list in 2023 over safety concerns, according to Ars Technica. The agency's scientists continue to say there is insufficient evidence that the peptides are effective, and that they carry potential risks. Part of the dispute, per the report, is that few or no human studies exist showing either benefit or harm — meaning the case for restricting the peptides and the case for allowing them both rest on a lack of direct human data.

How Was the Advisory Panel Changed Before Its Vote?

Kennedy's stated rationale leans on a July vote by an FDA advisory panel to add the six peptides back to the compounding list. But Ars Technica reports that Kennedy added eight new members to the 12-person committee before that vote, and at least six of those additions have ties to peptide-related businesses and clinics — a detail the outlet describes as raising "serious conflict-of-interest concerns."

What's Kennedy's Safety Argument?

Kennedy's policy argues that expanding legal access through compounding pharmacies will reduce use of peptides bought on the gray or black market from foreign manufacturers, which the policy says poses its own safety risk, according to Ars Technica. The policy frames existing hypothetical or "inferential" safety concerns as secondary to that gray-market risk — even though the underlying human safety data for the peptides themselves remains limited either way.

What to Watch

• Whether the FDA issues any formal response or legal challenge to a policy that overrides its own 2023 safety determination.
• Whether compounding pharmacies move quickly to begin selling the six peptides once the rule takes effect October 30.
• Whether lawmakers or outside ethics groups press for scrutiny of the advisory panel members with peptide-industry ties.
• Whether any human clinical data on the six peptides' safety or efficacy emerges following wider legal distribution.

AlterEgo — A keyboard for character voices. Five free persona rewrites a day.